These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

492 related articles for article (PubMed ID: 28332240)

  • 1. Lower urinary tract symptoms/benign prostatic hypertrophy and vascular function: Role of the nitric oxide-phosphodiesterase type 5-cyclic guanosine 3',5'-monophosphate pathway.
    Higashi Y
    Int J Urol; 2017 Jun; 24(6):412-424. PubMed ID: 28332240
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Lower urinary tract symptoms related to benign prostatic hyperplasia and erectile dysfunction: A systematic review].
    Peyronnet B; Seisen T; Phé V; Misrai V; de la Taille A; Rouprêt M
    Presse Med; 2017 Mar; 46(2 Pt 1):145-153. PubMed ID: 27745762
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Critical analysis of the relationship between sexual dysfunctions and lower urinary tract symptoms due to benign prostatic hyperplasia.
    Gacci M; Eardley I; Giuliano F; Hatzichristou D; Kaplan SA; Maggi M; McVary KT; Mirone V; Porst H; Roehrborn CG
    Eur Urol; 2011 Oct; 60(4):809-25. PubMed ID: 21726934
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhaled nitric oxide decreases pulmonary soluble guanylate cyclase protein levels in 1-month-old lambs.
    Thelitz S; Bekker JM; Ovadia B; Stuart RB; Johengen MJ; Black SM; Fineman JR
    J Thorac Cardiovasc Surg; 2004 May; 127(5):1285-92. PubMed ID: 15115984
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Rho/Rac exchange factor Vav2 controls nitric oxide-dependent responses in mouse vascular smooth muscle cells.
    Sauzeau V; Sevilla MA; Montero MJ; Bustelo XR
    J Clin Invest; 2010 Jan; 120(1):315-30. PubMed ID: 20038798
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Negative regulation of rho signaling by insulin and its impact on actin cytoskeleton organization in vascular smooth muscle cells: role of nitric oxide and cyclic guanosine monophosphate signaling pathways.
    Begum N; Sandu OA; Duddy N
    Diabetes; 2002 Jul; 51(7):2256-63. PubMed ID: 12086958
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PDE5 inhibitors for LUTS.
    Mouli S; McVary KT
    Prostate Cancer Prostatic Dis; 2009; 12(4):316-24. PubMed ID: 19687801
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endothelial dysfunction and vascular disease - a 30th anniversary update.
    Vanhoutte PM; Shimokawa H; Feletou M; Tang EH
    Acta Physiol (Oxf); 2017 Jan; 219(1):22-96. PubMed ID: 26706498
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cyclic guanosine monophosphate-enhancing reduces androgenic extracellular regulated protein kinases-phosphorylation/Rho kinase II-activation in benign prostate hyperplasia.
    Liu CM; Fan YC; Lo YC; Wu BN; Yeh JL; Chen IJ
    Int J Urol; 2014 Jan; 21(1):87-92. PubMed ID: 23692571
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phosphodiesterase type 5 inhibition reverts prostate fibroblast-to-myofibroblast trans-differentiation.
    Zenzmaier C; Kern J; Sampson N; Heitz M; Plas E; Untergasser G; Berger P
    Endocrinology; 2012 Nov; 153(11):5546-55. PubMed ID: 22948216
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination of phosphodiesterase-5 inhibitors and alpha-blockers in patients with benign prostatic hyperplasia: treatments of lower urinary tract symptoms, erectile dysfunction, or both?
    Carson CC
    BJU Int; 2006 Apr; 97 Suppl 2():39-43; discussion 44-5. PubMed ID: 16507053
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential role of type 5 phosphodiesterase inhibition in the treatment of congestive heart failure.
    Katz SD
    Congest Heart Fail; 2003; 9(1):9-15. PubMed ID: 12556672
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tadalafil for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: pathophysiology and mechanism(s) of action.
    Andersson KE; de Groat WC; McVary KT; Lue TF; Maggi M; Roehrborn CG; Wyndaele JJ; Melby T; Viktrup L
    Neurourol Urodyn; 2011 Mar; 30(3):292-301. PubMed ID: 21284024
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The mechanism of action of phosphodiesterase type 5 inhibitors in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia.
    Giuliano F; Ückert S; Maggi M; Birder L; Kissel J; Viktrup L
    Eur Urol; 2013 Mar; 63(3):506-16. PubMed ID: 23018163
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lower urinary tract symptoms, benign prostatic hyperplasia/benign prostatic enlargement and erectile dysfunction: are these conditions related to vascular dysfunction?
    Shimizu S; Tsounapi P; Shimizu T; Honda M; Inoue K; Dimitriadis F; Saito M
    Int J Urol; 2014 Sep; 21(9):856-64. PubMed ID: 24930630
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phosphodiesterase type 5 (PDE5) is co-localized with key proteins of the nitric oxide/cyclic GMP signaling in the human prostate.
    Ückert S; Waldkirch ES; Merseburger AS; Kuczyk MA; Oelke M; Hedlund P
    World J Urol; 2013 Jun; 31(3):609-14. PubMed ID: 23475211
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Resistance to the nitric oxide/cyclic guanosine 5'-monophosphate/protein kinase G pathway in vascular smooth muscle cells from the obese Zucker rat, a classical animal model of insulin resistance: role of oxidative stress.
    Russo I; Del Mese P; Doronzo G; Mattiello L; Viretto M; Bosia A; Anfossi G; Trovati M
    Endocrinology; 2008 Apr; 149(4):1480-9. PubMed ID: 18079207
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dipyridamole attenuates rebound pulmonary hypertension after inhaled nitric oxide withdrawal in postoperative congenital heart disease.
    Ivy DD; Kinsella JP; Ziegler JW; Abman SH
    J Thorac Cardiovasc Surg; 1998 Apr; 115(4):875-82. PubMed ID: 9576224
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Testosterone Deficiency and Endothelial Dysfunction: Nitric Oxide, Asymmetric Dimethylarginine, and Endothelial Progenitor Cells.
    Hotta Y; Kataoka T; Kimura K
    Sex Med Rev; 2019 Oct; 7(4):661-668. PubMed ID: 30987932
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of the nitric oxide-cyclic guanosine monophosphate pathway in experimental liver cirrhosis suggests phosphodiesterase-5 as potential target to treat portal hypertension.
    Schaffner D; Lazaro A; Deibert P; Hasselblatt P; Stoll P; Fauth L; Baumstark MW; Merfort I; Schmitt-Graeff A; Kreisel W
    World J Gastroenterol; 2018 Oct; 24(38):4356-4368. PubMed ID: 30344420
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.